Risk Score for carotid angioplasty

Original title: Risk Prediction for Adverse Events After Carotid Artery Stenting in Higher Surgical Risk Patients Reference: Neil J. Wimmer et al. 2012;43: 3218-3224 Stroke.

There are many patients with high surgical risk for carotid endarterectomy, either because of unfavorable anatomy, comorbidities or both. In this situation carotid angioplasty is a therapeutic option. However, no score has been developed to predict events in this specific group.

The study population comes from patients who were not randomized from the SAPPHIRE trial, (Stenting and Angioplasty with protection in Patients at High Risk for Endarterectomy), and entered into a prospective registry.

The objective was to develop and validate a score to predict death and stroke at 30 days in patients who received carotid angioplasty and who were at high surgical risk for endarterectomy.

We included 10,186 patients in total, between 2006 and 2010 of which (29.8%) had symptomatic lesions but all were high risk for surgery. At 30 days there was a 1.2% mortality rate (123 patients) and 3% suffered a stroke (301 patients). From this data the 10 independent predictors in the final model emerged.

Conclusion 

We developed and validated a score that predicts death and stroke at 30 days in patients who received carotid angioplasty and were at high risk for an endarterectomy.

Editorial Comment:

It is a quick and easy score with a clinical application that can help us with a difficult decision beside the patient’s bed. External validity is uncertain since all patients used the same filter and stent, (ANGIOGUARD + PRECISE). All patients received carotid angioplasty beyond the risk, all were out of surgery and medical treatment was not an option, so the score would be limited to deciding between different treatment strategies.

SOLACI.ORG

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...